NASA Johnson Space Center to Assist BiVACOR Inc. with Artificial Heart System

HOUSTON, Sept. 25, 2019 /PRNewswire/ — NASA Johnson Space Center will provide its unique, advanced risk-management services as part of a Space Act Agreement with BiVACOR Inc., Houston, in the company’s efforts to improve the robustness and reliability of its Total Artificial Heart (TAH) system – an implantable rotary bi-ventricular blood pump and associated external electronics.

News media are invited to the agreement’s signing ceremony, which begins at 1 p.m. Central Time, Tuesday Oct. 1, 2019 at the Gilruth Center (Discovery Room) off Space Center Boulevard adjacent to Johnson Space Center. Media wishing to attend should arrive no later than 12:30 p.m. at the Gilruth Center via Space Center Boulevard near the intersection of NASA Parkway.

The Reimbursable Space Act Agreement will utilize NASA’s expertise in Probabilistic Risk Assessment (PRA) with an initial scope of work allowing NASA to provide a PRA to BiVACOR to help the medical industry assess the risk of advanced ground breaking high reliability technology for medical components that must operate in extreme environments.

Attending the ceremony will be NASA JSC’s Director of Safety and Mission Assurance (S&MA) Russ DeLoach, S&MA Deputy Director Rex Walheim and Daniel Timms, Ph.D., BiVACOR biomedical engineer. They will be available for questions from media as part of the ceremony.

Media planning to attend should RSVP to the JSC Newsroom at 281-483-5111 by Monday, Sept. 30 in order to obtain a head count for seating at Gilruth.

The agreement with BiVACOR could have a significant impact on the medical community, by using NASA’s expertise in risk and reliability analysis.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nasa-johnson-space-center-to-assist-bivacor-inc-with-artificial-heart-system-300925513.html

SOURCE NASA

Staff

Recent Posts

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual…

1 hour ago

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…

1 hour ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by…

1 hour ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading…

1 hour ago

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year…

1 hour ago

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to May 3, 2024

MIAMI, March 29, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW)…

1 hour ago